Geron(DE:GON)
€0.86-0.00 (-0.35%)
DE:GON
Geron stock drug pipeline
€0.86
At close:-0.00 (-0.35%)
Geron (GON) Drug Pipeline
7 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Geron Corporation (DE:GON) have in its pipeline
Geron DE:GON is currently developing the following drugs: Imetelstat Sodium, Ruxolitinib, Imetelstat Sodium, Pacritinib, Momelotinib, Fedratinib, Imetelstat, Best Available Therapy (BAT), Imetelstat 4.7 Mg/Kg, Imetelstat 9.4 Mg/Kg, Imetelstat, Bevacizumab, Paclitaxel, Imetelstat Sodium, Imetelstat (7.5 Mg/Kg), Lenalidomide Standard Of Care, Imetelstat (9.4 Mg/Kg), Bevacizumab, Imetelstat, Grn163l, Imetelstat Sodium (Grn163l). These drug candidates are in various stages of clinical development as the company works toward FDA approval.

